Skip to content

AdaptHealth AHCO Diabetes Health — Goodwill

Other segment segments

Sleep Health
$1.6B+1.1%
Respiratory Health
$692.66M+2.4%
Wellness at Home
$192.19M+15.9%

Similar metrics at other companies

Ziff Davis logo
ZDHealth & Wellness — Goodwill
$403.87M-0.1%
Leidos Holdings logo
LDOSHealth — Goodwill
$1.34B
Ashland logo
ASHLife Sciences — Goodwill
$462M-42.8%
ExlService Holdings logo
EXLSHealthcare and Life Sciences — Goodwill
$189.57M0.0%
Globe Life logo
GLHealth — Goodwill
$180.84M0.0%
National Healthcare logo
NHCInpatient Services — Goodwill
$5.92M0.0%

Other financials

Income statement

See full
Revenue$819.8M+5.4%
Gross profit$111.5M-7.4%
Operating income$5.5M-76.3%
Net income-$16.0M-123%
EPS (diluted)-$0.12-140%

Balance sheet

See full
Cash & equivalents$48.0M-10.6%
Total debt$2.0B-4.9%
Total equity$1.5B-3.9%
Total assets$4.4B-0.3%

Cash flow

See full
Operating cash flow$93.7M-1.9%
CapEx$121.2M+26.8%
Free cash flow-$27.5M-47,297%

Valuation

See full
Market cap$1.36B+20.5%
Enterprise value$3.32B+4.3%
P/S0.4×+0.1×

Profitability

See full
Gross margin18.3%-1.6pp
Operating margin8%+6.9pp
Net margin-2.4%-5.1pp
FCF margin5.8%-2.6pp

Returns & leverage

See full
Return on equity-5.2%-10.8pp
Debt / equity1.3×0.0×
Current ratio0.9×-0.4×

Where this comes from

Reported directly by AdaptHealth in its filing.

Tagged under the XBRL concept us-gaap:Goodwill.

The official record: AdaptHealth’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about AdaptHealth's diabetes health — goodwill.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is AdaptHealth's diabetes health — goodwill?
AdaptHealth (AHCO) reported diabetes health — goodwill of $83.8M in Q1 2026.
How has AdaptHealth's diabetes health — goodwill changed year-over-year?
AdaptHealth's diabetes health — goodwill decreased by 60.4% year-over-year, from $211.8M to $83.8M.
What does diabetes health — goodwill mean?
Represents the intangible asset value recorded when the purchase price of a diabetes-related business acquisition exceeds the fair value of its identifiable net assets. It serves as a measure of the premium paid for expected future economic benefits, brand reputation, and market synergies.